Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission-Reference-Cited by-同舟云学术

Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission

Published:2011 Issue:2 Volume:58 Page:95-100
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Konishi Toshiaki¹,Okamoto Yasuyuki²,Ueda Miki¹,Fukuda Yoshiko²,Harusato Ichiko¹,Tsukamoto Yuka²,Hamada Noboru¹

Affiliation:

1. Sumire Hospital, Osaka, Japan

2. Sumire Clinic, Osaka, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.jstage.jst.go.jp/article/endocrj/58/2/58_K10E-262/_pdf

Reference30 articles.

1. ANTITHYROID DRUGS IN THE TREATMENT OF HYPERTHYROIDISM OF Graves' DISEASE: LONG-TERM FOLLOW-UP OF 434 PATIENTS

2. 2. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR et al (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol (Copenh) 120: 689-701.

3. 3. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.

4. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association

5. 5. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN (1996) Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. BMJ 313: 539-544.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration;Endocrinology and Metabolism;2024-08-31

2. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease;The Journal of Clinical Endocrinology & Metabolism;2024-07-09

3. Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves’ hyperthyroidism: a randomized trial and a risk-scoring model;Endocrine;2024-01-02

4. Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy;International Journal of Endocrinology and Metabolism;2024-01-02

5. Long-term thionamide antithyroid treatment of Graves' disease;Best Practice & Research Clinical Endocrinology & Metabolism;2023-03